SCHEMBL832659

SCHEMBL832659

CC(C)c1nc(-c2ccc(Cl)cc2)cc(C(F)(F)F)c1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP3 P05413 1/20 0.46
FABP4 P15090 1/20 0.46
FABP5 Q01469 1/20 0.46
POLB P06746 2/20 0.46
MAPT P10636 2/20 0.46
ACHE P22303 1/20 0.44
CTRC Q99895 3/20 0.43
PPARA Q07869 1/20 0.43
ALDH1A1 P00352 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
DHODH Q02127 1/20 0.42
ANO1 Q5XXA6 1/20 0.42
RXFP1 Q9HBX9 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41
RAB9A P51151 1/20 0.41
ATM Q13315 1/20 0.41
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL830473 0.87 MAPT (0.47) POLBMAPTACHEALDH1A1L3MBTL1
SCHEMBL830805 0.82 POLB (0.46) POLBMAPTACHECTRCALDH1A1
SCHEMBL831291 0.82 POLB (0.43) POLBMAPTACHECTRCALDH1A1
SCHEMBL830165 0.82 ALDH1A1 (0.43) POLBMAPTACHECTRCALDH1A1
SCHEMBL829804 0.81 POLB (0.45) POLBMAPTACHECTRCALDH1A1
SCHEMBL831824 0.79 HPGD (0.48) POLBMAPTACHECTRCALDH1A1
SCHEMBL829557 0.79 XDH (0.45) POLBMAPTACHECTRCALDH1A1
SCHEMBL830423 0.78 FABP3 (0.46) FABP3FABP4FABP5CTRCPPARA
SCHEMBL832584 0.77 ALDH1A1 (0.50) POLBMAPTACHECTRCALDH1A1
SCHEMBL830022 0.77 POLB (0.42) POLBMAPTACHECTRCALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143411-B2 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2012-03-27 US disclosed
US-8143411-B2 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2012-03-27 US disclosed
US-8143411-B2 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2012-03-27 US disclosed
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2010-09-16 US disclosed
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2010-09-16 US disclosed
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2010-09-16 US disclosed
WO-2009033561-A1 SUBSTITUTED 6-PHEYLNICOTINIC ACIDS AND THE USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use SLC5A6, FABP3, NAPRT FABP3 2/4885FABP4 183/4885FABP5 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.